EDAP TMS S.A. Reports Record Q1 2026 Earnings Driven by HIFU Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy EDAP?
Source: seekingalpha
- Record Revenue: EDAP TMS S.A. reported total revenue of $17.8 million for Q1 2026, exceeding analysts' expectations of $16.6 million, primarily driven by Focal One robotic HIFU sales reaching $11.6 million, demonstrating the company's successful shift to higher-margin business segments.
- Multi-Site Expansion: The company has now seen 11 U.S. hospitals and health networks invest in and launch two or more Focal One robotic HIFU programs, indicating a significant increase in market penetration that is expected to further drive future revenue growth.
- International Momentum: Following the French National Health System's decision to provide universal coverage for the Focal One HIFU procedure, EDAP achieved its first cash sale in France, marking a pivotal expansion in its global operations and revenue diversification.
- Stable Financial Outlook: The company reiterated its 2026 core HIFU revenue guidance of $50 million to $54 million, representing a 34% to 45% year-over-year growth, while also securing approximately $14 million from the European Investment Bank credit facility at the end of Q1, enhancing its financial flexibility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EDAP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EDAP
Wall Street analysts forecast EDAP stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.160
Low
2.50
Averages
8.25
High
14.00
Current: 4.160
Low
2.50
Averages
8.25
High
14.00
About EDAP
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EDAP TMS S.A. Reports Record Q1 2026 Earnings Driven by HIFU Sales
- Record Revenue: EDAP TMS S.A. reported total revenue of $17.8 million for Q1 2026, exceeding analysts' expectations of $16.6 million, primarily driven by Focal One robotic HIFU sales reaching $11.6 million, demonstrating the company's successful shift to higher-margin business segments.
- Multi-Site Expansion: The company has now seen 11 U.S. hospitals and health networks invest in and launch two or more Focal One robotic HIFU programs, indicating a significant increase in market penetration that is expected to further drive future revenue growth.
- International Momentum: Following the French National Health System's decision to provide universal coverage for the Focal One HIFU procedure, EDAP achieved its first cash sale in France, marking a pivotal expansion in its global operations and revenue diversification.
- Stable Financial Outlook: The company reiterated its 2026 core HIFU revenue guidance of $50 million to $54 million, representing a 34% to 45% year-over-year growth, while also securing approximately $14 million from the European Investment Bank credit facility at the end of Q1, enhancing its financial flexibility.
See More
EDAP TMS S.A. Q1 Earnings Highlights
- Earnings Performance: EDAP TMS S.A. reported a Q1 GAAP EPS of -$0.24, missing expectations by $0.01, while revenue reached $17.81 million, reflecting a 24.5% year-over-year increase and exceeding estimates by $1.21 million, indicating strong revenue growth momentum.
- HIFU Revenue Growth: The company experienced a 78% year-over-year increase in HIFU revenue for Q1, demonstrating sustained market demand for this business line and reinforcing its position in the high-intensity focused ultrasound treatment sector.
- U.S. HIFU Procedures Growth: There was a 53% year-over-year growth in U.S. HIFU procedures in Q1, showcasing the effectiveness of the company's expansion strategy in the U.S. market, which is expected to drive future revenue growth.
- Future Outlook: The company reiterated its revenue guidance, projecting core HIFU business revenue to be between $50 million and $54 million, representing a year-over-year growth of 34% to 45%, while non-core business revenue is expected to range from $22 million to $26 million, reflecting confidence in future growth prospects.
See More
EDAP Reports Record First Quarter HIFU Revenue Growth
- HIFU Revenue Surge: EDAP achieved $11.6 million in HIFU revenue for Q1 2026, marking a 78% year-over-year increase, which reflects the company's strong performance in a high-growth market and is expected to enhance shareholder value.
- Record Procedure Volumes: U.S. Focal One procedure volumes grew by 53% year-over-year, reaching record levels, indicating the company's success in market penetration and customer demand, thereby strengthening its competitive position in the medical device sector.
- International Market Expansion: The company secured capital sales of Focal One systems in the UK, France, and Hungary, marking the first time hospitals are investing in these systems for treating prostate cancer and deep infiltrating endometriosis, highlighting strategic international growth.
- HIFI-2 Study Results: The HIFI-2 study results demonstrate the potential of Focal One HIFU for treating men with recurrent prostate cancer, further solidifying its market position as a non-invasive treatment option and signaling future growth opportunities.
See More
EDAP TMS S.A. to Announce Q1 Earnings on May 7
- Earnings Announcement: EDAP TMS S.A. is set to release its Q1 2023 earnings on May 7 before market open, with a consensus EPS estimate of -$0.21, reflecting a 10.5% year-over-year decline, indicating profitability challenges ahead.
- Revenue Expectations: Analysts project revenue to reach $16.6 million, representing a 16.1% year-over-year increase, suggesting that despite challenges, the company maintains a positive trajectory in revenue growth.
- Historical Performance Review: Over the past year, EDAP has only beaten EPS estimates 25% of the time and has not exceeded revenue expectations, highlighting volatility in the company's profitability and revenue generation.
- Future Outlook: EDAP TMS aims for $50 million to $54 million in HIFU revenue by 2026, indicating ongoing strategic expansion in both U.S. and international markets.
See More
EDAP to Announce Q1 2026 Financial Results on May 7
- Earnings Announcement: EDAP TMS SA will release its Q1 2026 financial results before market open on May 7, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: A conference call will be held on the same day at 8:30 AM EDT, hosted by CEO Ryan Rhodes and other executives, aimed at providing investors with an in-depth analysis of the financial results and future outlook.
- Technological Leadership: EDAP TMS is a global leader in robotic energy-based therapies, developing and distributing various minimally invasive medical devices, showcasing its ongoing efforts in medical technology innovation.
- Focal One® Product Overview: The Focal One® system is widely used in Europe and the U.S. for prostate focal therapy, with potential expansion into other indications, further solidifying its market position.
See More
EDAP Reports 39% Revenue Growth in HIFU for 2025
- HIFU Revenue Growth: EDAP achieved a 39% revenue increase in its core HIFU business for 2025, reaching EUR 33.1 million, primarily driven by strong demand in the U.S. market, demonstrating the company's market penetration capabilities in high-growth sectors.
- Global Sales Milestone: In Q4 2025, EDAP recorded 15 Focal One device placements worldwide, with 14 being cash sales, marking a robust performance in equipment sales and further solidifying its market leadership position.
- Financial Challenges: Despite the growth in HIFU revenue, total revenue for 2025 was EUR 62.4 million, a 3% decline year-over-year, primarily due to a 27% drop in non-core distribution and ESWL businesses, which poses pressure on the company's overall financial health.
- Future Outlook: The company expects HIFU revenue in 2026 to range from USD 50 million to USD 54 million, representing a growth of 34% to 45%, and plans to transition to a new ultrasound engine to mitigate tariff impacts, thereby enhancing margins and competitive positioning.
See More
EDAP TMS S.A. Reports Record Q1 2026 Earnings Driven by HIFU Sales
- Record Revenue: EDAP TMS S.A. reported total revenue of $17.8 million for Q1 2026, exceeding analysts' expectations of $16.6 million, primarily driven by Focal One robotic HIFU sales reaching $11.6 million, demonstrating the company's successful shift to higher-margin business segments.
- Multi-Site Expansion: The company has now seen 11 U.S. hospitals and health networks invest in and launch two or more Focal One robotic HIFU programs, indicating a significant increase in market penetration that is expected to further drive future revenue growth.
- International Momentum: Following the French National Health System's decision to provide universal coverage for the Focal One HIFU procedure, EDAP achieved its first cash sale in France, marking a pivotal expansion in its global operations and revenue diversification.
- Stable Financial Outlook: The company reiterated its 2026 core HIFU revenue guidance of $50 million to $54 million, representing a 34% to 45% year-over-year growth, while also securing approximately $14 million from the European Investment Bank credit facility at the end of Q1, enhancing its financial flexibility.
See More
EDAP TMS S.A. Q1 Earnings Highlights
- Earnings Performance: EDAP TMS S.A. reported a Q1 GAAP EPS of -$0.24, missing expectations by $0.01, while revenue reached $17.81 million, reflecting a 24.5% year-over-year increase and exceeding estimates by $1.21 million, indicating strong revenue growth momentum.
- HIFU Revenue Growth: The company experienced a 78% year-over-year increase in HIFU revenue for Q1, demonstrating sustained market demand for this business line and reinforcing its position in the high-intensity focused ultrasound treatment sector.
- U.S. HIFU Procedures Growth: There was a 53% year-over-year growth in U.S. HIFU procedures in Q1, showcasing the effectiveness of the company's expansion strategy in the U.S. market, which is expected to drive future revenue growth.
- Future Outlook: The company reiterated its revenue guidance, projecting core HIFU business revenue to be between $50 million and $54 million, representing a year-over-year growth of 34% to 45%, while non-core business revenue is expected to range from $22 million to $26 million, reflecting confidence in future growth prospects.
See More
EDAP Reports Record First Quarter HIFU Revenue Growth
- HIFU Revenue Surge: EDAP achieved $11.6 million in HIFU revenue for Q1 2026, marking a 78% year-over-year increase, which reflects the company's strong performance in a high-growth market and is expected to enhance shareholder value.
- Record Procedure Volumes: U.S. Focal One procedure volumes grew by 53% year-over-year, reaching record levels, indicating the company's success in market penetration and customer demand, thereby strengthening its competitive position in the medical device sector.
- International Market Expansion: The company secured capital sales of Focal One systems in the UK, France, and Hungary, marking the first time hospitals are investing in these systems for treating prostate cancer and deep infiltrating endometriosis, highlighting strategic international growth.
- HIFI-2 Study Results: The HIFI-2 study results demonstrate the potential of Focal One HIFU for treating men with recurrent prostate cancer, further solidifying its market position as a non-invasive treatment option and signaling future growth opportunities.
See More
EDAP TMS S.A. to Announce Q1 Earnings on May 7
- Earnings Announcement: EDAP TMS S.A. is set to release its Q1 2023 earnings on May 7 before market open, with a consensus EPS estimate of -$0.21, reflecting a 10.5% year-over-year decline, indicating profitability challenges ahead.
- Revenue Expectations: Analysts project revenue to reach $16.6 million, representing a 16.1% year-over-year increase, suggesting that despite challenges, the company maintains a positive trajectory in revenue growth.
- Historical Performance Review: Over the past year, EDAP has only beaten EPS estimates 25% of the time and has not exceeded revenue expectations, highlighting volatility in the company's profitability and revenue generation.
- Future Outlook: EDAP TMS aims for $50 million to $54 million in HIFU revenue by 2026, indicating ongoing strategic expansion in both U.S. and international markets.
See More
EDAP to Announce Q1 2026 Financial Results on May 7
- Earnings Announcement: EDAP TMS SA will release its Q1 2026 financial results before market open on May 7, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: A conference call will be held on the same day at 8:30 AM EDT, hosted by CEO Ryan Rhodes and other executives, aimed at providing investors with an in-depth analysis of the financial results and future outlook.
- Technological Leadership: EDAP TMS is a global leader in robotic energy-based therapies, developing and distributing various minimally invasive medical devices, showcasing its ongoing efforts in medical technology innovation.
- Focal One® Product Overview: The Focal One® system is widely used in Europe and the U.S. for prostate focal therapy, with potential expansion into other indications, further solidifying its market position.
See More
EDAP Reports 39% Revenue Growth in HIFU for 2025
- HIFU Revenue Growth: EDAP achieved a 39% revenue increase in its core HIFU business for 2025, reaching EUR 33.1 million, primarily driven by strong demand in the U.S. market, demonstrating the company's market penetration capabilities in high-growth sectors.
- Global Sales Milestone: In Q4 2025, EDAP recorded 15 Focal One device placements worldwide, with 14 being cash sales, marking a robust performance in equipment sales and further solidifying its market leadership position.
- Financial Challenges: Despite the growth in HIFU revenue, total revenue for 2025 was EUR 62.4 million, a 3% decline year-over-year, primarily due to a 27% drop in non-core distribution and ESWL businesses, which poses pressure on the company's overall financial health.
- Future Outlook: The company expects HIFU revenue in 2026 to range from USD 50 million to USD 54 million, representing a growth of 34% to 45%, and plans to transition to a new ultrasound engine to mitigate tariff impacts, thereby enhancing margins and competitive positioning.
See More
